Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Grenoble – page 50

663 clinical trials in Grenoble, France. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Grenoble at a glance
663
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

663 trials in Grenoble

Open in trial search

Colitis ulcerative

Not recruiting

Study on the Effects of GS-5290 for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:(Phosphonooxy)Methyln-[(S)-[1-(Bicyclo[1.1.1]Pentan1-Yl)-1H-1,2,3-Triazol-4-Yl](2-Methyl-1-Oxo-1,2-Dihydroisoquinolin-5-Yl)Methyl]-N-{8-Chloro-3-Cyano-4-[(2,2-Dimethylpropyl)Amino]Quinolin-6-Yl]Carbamate
  • Sponsor:Gilead Sciences Inc.

Hepatocellular carcinoma

Not recruiting

Study of Atezolizumab, Bevacizumab, and Tiragolumab for Patients with Untreated Advanced or Metastatic Liver Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Myelodysplastic syndrome

Not recruiting

Study Comparing Luspatercept and Epoetin Alfa for Treating Anemia in Patients with Low-Risk Myelodysplastic Syndrome Who Are Not Dependent on Blood Transfusions

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Epoetin Alfa
  • Sponsor:Celgene Corp.

Complications of transplanted kidney+1

Not recruiting

Study on ARGX-117 for Improving Kidney Function in Patients with Delayed Graft Function After Deceased Donor Transplant

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Prostate cancer

Not recruiting

Study on the Effectiveness and Safety of Apalutamide and GnRH Agonist in Patients with High-Risk Prostate Cancer Undergoing Radiation Therapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Janssen Cilag International

Dry eye+1

Not recruiting

Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Kidney transplant rejection

Not recruiting

Study on Tegoprubart for Preventing Kidney Transplant Rejection in Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:AT-1501
  • Sponsor:Eledon Pharmaceuticals Inc.

Endometrial cancer+6

Not recruiting

Study on Pembrolizumab, Lenvatinib, and Belzutifan for Patients with Liver, Colon, Pancreatic, Bile Duct, Gallbladder, Endometrial, or Esophageal Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

IgA nephropathy

Not recruiting

Study on the Long-term Safety and Effectiveness of Sibeprenlimab for Patients with Immunoglobulin A Nephropathy (IgAN)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sibeprenlimab
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Deep vein thrombosis+1

Not recruiting

Study on the Effectiveness and Safety of BAY 3018250 and Low Molecular Weight Heparin for Patients with Proximal Deep Vein Thrombosis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BAY 3018250
  • Sponsor:Bayer AG

Crohn's disease

Not recruiting

Study on Managing Moderate Postoperative Recurrence in Crohn's Disease with Infliximab for Patients After Ileocolonic Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:Groupe D'etude Therapeutique Des Affections Inflammatoires Du Tube Digestif

Hepatocellular carcinoma

Not recruiting

Study on the Safety and Effectiveness of TheraSphere, Durvalumab, and Tremelimumab for Patients with Liver Cancer (Hepatocellular Carcinoma)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Biocompatibles UK Limited

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Grenoble

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focusing on head and neck cancers, multiple myeloma, and various types of leukemia. Studies evaluate novel combination therapies and targeted treatments for improved patient outcomes.

  • Advanced NSCLC Treatment Studies
  • Gastric Cancer Immunotherapy
  • Hematologic Malignancies

Innovative approaches combining immunotherapy with standard treatments are showing promise in treating various forms of cancer.

02 Transplant Medicine

Clinical investigations examining kidney transplant outcomes and rejection prevention. Research focuses on new therapeutic approaches for managing transplant-related complications.

  • Antibody-Mediated Rejection
  • Novel Immunosuppression Strategies
  • Long-term Graft Survival

Studies aim to improve transplant success rates and reduce rejection incidents through innovative medication protocols.

03 Neurological Disorders

Research into narcolepsy and multiple sclerosis treatments, evaluating new therapeutic approaches for better symptom management and disease control.

  • Sleep Disorder Management
  • MS Treatment Innovations
  • Neurological Disease Progression

Cutting-edge treatments being developed to address both rare and common neurological conditions.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.